Browse by ▼

Exelixis

  • 2 Biotech Companies With Multi-Bagger Potential

    By Greg Williamson - April 18, 2013 | Tickers: CELG, EXEL, VRTX

    Some investors consider speculation to be a dirty word, but it can be an important component of a diversified portfolio. Although speculative stocks have an increased level of risk, they also have enormous reward potential. The following four keys will allow you to improve your chances of hitting a home run with speculative stocks, while ensuring that your portfolio is protected:

    1.) Limit your speculative holdings to between 10% to more »

  • Prognosis Positive: Medical Growth Stocks to Watch

    By Matt Swayne - January 29, 2013 | Tickers: ALNY, CELG, EBS, EXEL

    Skyrocketing healthcare costs will not be solved by politicians. Why do I say this? Because, let me ask you, when have politicians solved anything?

    Go ahead. Take your time. I’ll wait.

    Politicians may struggle to tame medical costs, but medical research firms are new treatments for many of the world’s most devastating -- and costly -- diseases. This can lead to new less expensive cures and a healthier and more more »

  • One Biotech Pony, Lots of Tricks

    By Reuben Brewer - January 22, 2013 | Tickers: BMY, EXEL, MRK

    Exelixix (Nasdaq: EXEL) got some good news last year when the Food and Drug Administration approved COMETRIQ for the treatment of progressive, metastatic medullary thyroid cancer. While the company is putting all of its effort behind this one drug, it looks like this pony might know a lot more than one trick. That could turn it into a franchise drug and a big money maker.

  • Biotech: Core and Explore

    By Reuben Brewer - January 22, 2013 | Tickers: ALXN, AMGN, EXEL | Editor's Choice

    When it comes to finding new drugs, biotechs are often at the leading edge. While that can lead to huge profits, it also leads to frequent flame outs. With a small number of large biotech firms, investors interested in the area would do well to use a core and explore approach to limit their downside risk.

  • What Are Insiders Buying Recently?

    By Meena Krishnamsetty - December 13, 2012 | Tickers: BRKR, CLSN, DF, EXEL

    Our database of insider trading filings allows us to pick out companies that have seen recent insider purchases- studies show that on average stocks bought by insiders tend to beat the market- and take a brief look at the company to see if it might be worth investigating further. It’s impossible to buy every stock that insiders are buying, but it’s certainly possible to use insider buying as more »

  • Taking a Deeper Look into Four Picks from Cramer's Lightning Round

    By Dr. Osman Gulseven - November 21, 2012 | Tickers: EXEL, QCOM, O, SODA

    CNBC's Mad Money show is exactly what the title implies: a mad show. Jim Cramer, the host and former hedge fund manager, presents market insights and offers useful investing ideas. The “Lightning Round,” is certainly the most fun part of the show. During this part, viewers ask Cramer to make a call on several stocks. Cramer needs just a few seconds to decide on a rating. I believe it more »

  • Biopharmaceutical Stocks: Possible Catalysts in November (Part I)

    By Jorge Aura - November 13, 2012 | Tickers: ACAD, CPRX, DVAX, EXEL, THRX

    A good investment strategy is to anticipate future movements of biopharmaceutical companies. These companies are typically reevaluated weeks before presenting results of their studies or future meetings with the FDA.

    The first company that has an important meeting with the FDA is Dynavax Technologies (NASDAQ: DVAX). On Aug. 28, 2012 the company announced that the U.S. Food and Drug Administration (FDA) had informed the company that its Vaccines and more »